<qa>  What is the unmet need for new therapies to control inflammation in DLE?There is an unmet need for new therapies to control inflammation in discoid lupus erythematosus DLE. A significant proportion of DLE patients with or without systemic lupus erythematosus SLE are resistant to conventional therapies and DLE may be exacerbated by B cell depletion therapy.There is no clinical guideline or algorithm on how to manage patients with DLE who have refractory disease to the first line agents, anti-malarials. If left untreated, uncontrolled inflammation will lead to permanent disfiguring and irreversible scar to the patient, thus pose a major cosmetic issue and significantly impair the quality of life. 